NASDAQ:IRWD Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis $0.74 +0.00 (+0.04%) As of 07/3/2025 03:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Ironwood Pharmaceuticals Stock (NASDAQ:IRWD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IRWD alerts:Sign Up Key Stats Today's Range$0.73▼$0.7750-Day Range$0.57▼$0.9752-Week Range$0.53▼$7.11Volume1.03 million shsAverage Volume2.57 million shsMarket Capitalization$119.75 millionP/E RatioN/ADividend YieldN/APrice Target$4.78Consensus RatingHold Company Overview Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. Read More Ironwood Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreIRWD MarketRank™: Ironwood Pharmaceuticals scored higher than 92% of companies evaluated by MarketBeat, and ranked 79th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingIronwood Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageIronwood Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ironwood Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth150.00% Earnings GrowthEarnings for Ironwood Pharmaceuticals are expected to grow by 150.00% in the coming year, from $0.10 to $0.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ironwood Pharmaceuticals is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ironwood Pharmaceuticals is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Ironwood Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.91% of the float of Ironwood Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIronwood Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ironwood Pharmaceuticals has recently decreased by 7.05%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIronwood Pharmaceuticals does not currently pay a dividend.Dividend GrowthIronwood Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.4 / 5Environmental Score-2.94 Percentage of Shares Shorted4.91% of the float of Ironwood Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIronwood Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ironwood Pharmaceuticals has recently decreased by 7.05%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for IRWD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Ironwood Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ironwood Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.70% of the stock of Ironwood Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Ironwood Pharmaceuticals' insider trading history. Receive IRWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IRWD Stock News HeadlinesIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives $4.78 Average Target Price from AnalystsJune 28, 2025 | americanbankingnews.comPacer Advisors, Inc. Expands Stake in Ironwood Pharmaceuticals Inc.May 8, 2025 | gurufocus.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.July 6 at 2:00 AM | Porter & Company (Ad)Pacer Advisors, Inc. Reduces Stake in Ironwood Pharmaceuticals Inc.May 8, 2025 | gurufocus.comIronwood Pharmaceuticals Reports First Quarter 2025 ResultsMay 7, 2025 | businesswire.comIronwood Pharmaceuticals to Participate in The Citizens Life Sciences ConferenceApril 30, 2025 | businesswire.comIronwood Raises 2025 Adj. EBITDA OutlookApril 26, 2025 | nasdaq.comIronwood backs FY25 revenue view $260M-$290M, consensus $287.07MApril 26, 2025 | markets.businessinsider.comSee More Headlines IRWD Stock Analysis - Frequently Asked Questions How have IRWD shares performed this year? Ironwood Pharmaceuticals' stock was trading at $4.43 at the beginning of 2025. Since then, IRWD stock has decreased by 83.3% and is now trading at $0.74. How were Ironwood Pharmaceuticals' earnings last quarter? Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its quarterly earnings results on Wednesday, May, 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.09. The biotechnology company earned $41.14 million during the quarter, compared to analysts' expectations of $67.02 million. Ironwood Pharmaceuticals had a negative trailing twelve-month return on equity of 1.87% and a negative net margin of 9.89%. How do I buy shares of Ironwood Pharmaceuticals? Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ironwood Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ironwood Pharmaceuticals investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings5/07/2025Today7/05/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryBiotechnology Current SymbolNASDAQ:IRWD CIK1446847 Webwww.ironwoodpharma.com Phone(617) 621-7722Fax617-494-0480Employees220Year FoundedN/APrice Target and Rating Average Stock Price Target$4.78 High Stock Price Target$14.00 Low Stock Price Target$0.70 Potential Upside/Downside+546.4%Consensus RatingHold Rating Score (0-4)2.13 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.20) Trailing P/E RatioN/A Forward P/E Ratio7.40 P/E GrowthN/ANet Income$880 thousand Net Margins-9.89% Pretax Margin7.54% Return on Equity-1.87% Return on Assets-3.93% Debt Debt-to-Equity RatioN/A Current Ratio3.34 Quick Ratio3.34 Sales & Book Value Annual Sales$351.41 million Price / Sales0.34 Cash Flow$0.05 per share Price / Cash Flow15.49 Book Value($1.88) per share Price / Book-0.39Miscellaneous Outstanding Shares161,820,000Free Float141,269,000Market Cap$119.75 million OptionableOptionable Beta0.30 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:IRWD) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.